对于HFpEF的老年患者风险分层和预后的心脏标志物
Omar Abusedera1, Jana Sherif1, Leena Karar1
1School of Medicine, Royal College of Surgeons in Ireland-Bahrain, Al-Muharraq, Bahrain.
Frontiers in medicine
|March 6, 2026
概括
生物标志物如BNP,热波宁,sST2和加列-3有助于诊断和预测心力衰竭的老年患者的治疗结果,其中包括心力衰竭的保存喷射分数 (HFpEF). 综合方法可以改善风险分层和个性化管理.
科学领域:
- 心脏病学 心脏病学
- 生物标志物研究 生物标志物研究
- 老年医学 老年医学
背景情况:
- 保持喷射分数 (HFpEF) 的心力衰竭在老年人,尤其是女性中越来越令人担忧.
- 复杂的病理生理学涉及诸如高血压,糖尿病和功能障碍等并发症,使诊断和预后复杂化.
- 循环生物标志物对于理解心肌张力,纤维化,炎症和HFpEF损伤至关重要.
研究的目的:
- 在老年HFpEF患者中审查关键心脏生物标志物的诊断和预后效用.
- 专注于BNP/NT-proBNP,高灵敏度热素,sST2和加列-3.
- 评估它们在反映潜在生物过程中的作用.
主要方法:
- 在HFpEF中对心脏生物标志物的现有文献进行小审查.
- 分析所选生物标志物的诊断和预后作用.
- 考虑对老年人生物标志物解释的影响.
主要成果:
- BNP/NT-proBNP是HFpEF诊断和预后的关键,尽管受功能和年龄的影响.
- 高灵敏度的热素通过表明慢性心肌损伤来预测死亡率和住院情况.
- sST2 和 Galectin-3 反映炎症和纤维化,提供预后价值,特别是 HFpEF 中的 Galectin-3.
结论:
- 生物标志物提供了对HFpEF病理生理学的补充见解.
- 综合墙壁应力,损伤,炎症和纤维化标志物的多标志物策略可以提高诊断准确度.
- 个性化管理策略可以通过综合生物标志物数据来指导,以改善风险分层.
相关概念视频
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
668
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
668
01:30Heart Failure IV: Classification and Diagnostic Evaluation
503
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
503
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
1.0K
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.0K
01:17Pathophysiology of Heart Failure
4.2K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.2K
01:30Heart Failure V: Medical Management
441
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
441
01:30Cardiomyopathy II: Dilated Cardiomyopathy
687
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
687